Telix and DuChemBio - South Korea Partnership
Filed with ASX · · 2 pages · English
Melbourne (Australia) and Seoul (South Korea) – 3 December 2020. Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces it has entered into a commercialisation and partnership agreement with DuChemBio Co, Ltd. (DuChemBio), the leading South Korean 68 radiopharmaceutical company, for Telix’s prostate cancer imaging product TLX591-CDx ( Ga- PSMA-11). DuChemBio has the large
Telix Pharmaceuticals Limited on 6ix
In the deck
Earlier from Telix Pharmaceuticals
- Briefing for Investor call - TheraPharm GmbH Acquisition
- Acquisition of TheraPharm GmbH - Investor Call
- Telix Acquires TheraPharm GmbH
- Prostate Cancer Therapy FDA Meeting Update
- NDA for Prostate Cancer Imaging accepted by US FDA
Later from Telix Pharmaceuticals
- ProstACT Phase III Study Clinical Development Update
- TGA Priority Review Granted for Prostate Cancer Imaging
- FDA New Drug Application for TLX591-CDx Proceeds to Review
- Telix Completes Acquisition of TheraPharm GmbH
- IP Agreement with U Southampton for access to TRALA data
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals